ALBUTEROL SULFATE; IPRATROPIUM BROMIDE | A202496 | THE RITEDOSE CORP
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from The Ritedose Corporation FDA-2020-P-0102 · 5 docket documents The Ritedose Corporation filed this citizen petition under 505(j) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA designate ANDA 202496 as the reference standard for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, 0.5 mg/3 mg per 3 mL, because the original referenc | 505(q) | 2020-01-08 | WithdrawnUnverified summary | The Ritedose Corporation |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0855
per ml
Lowest NADAC/Unit
$0.0812
per ml
Brand NDCs
0
Generic NDCs
12
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 69097084064IPRATROPIUM-ALBUTEROL 0.5-3(2.5) MG/3 ML | $0.0855 | ML | Generic | — | 2026-08-19 |
| 76204060012IPRATROPIUM-ALBUTEROL 0.5-3(2.5) MG/3 ML | $0.0855 | ML | Generic | — | 2026-08-19 |
| 00378967160IPRATROPIUM-ALBUTEROL 0.5-3(2.5) MG/3 ML | $0.0855 | ML | Generic | — | 2026-08-19 |
| 76204060060IPRATROPIUM-ALBUTEROL 0.5-3(2.5) MG/3 ML | $0.0855 | ML | Generic | — | 2026-08-19 |
| 69097084053IPRATROPIUM-ALBUTEROL 0.5-3(2.5) MG/3 ML | $0.0812 | ML | Generic | — | 2026-08-19 |
| 76204060001IPRATROPIUM-ALBUTEROL 0.5-3(2.5) MG/3 ML | $0.0812 | ML | Generic | — | 2026-08-19 |
Showing 6 of 12 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.